GERA

Gera is a biotechnology company focused on developing novel therapies for fibrotic and inflammatory diseases by targeting the interleukin 11 (IL-11) pathway. The company's research is based on the discovery that IL-11 is a critical driver of fibrosis across multiple organs, including the heart, lungs, kidneys, and liver. By inhibiting IL-11 signaling using monoclonal antibodies or small molecules, Gera aims to reverse existing fibrosis and prevent further organ damage. Their pipeline currently targets high-unmet-need indications such as nonalcoholic steatohepatitis (NASH), chronic kidney disease, and idiopathic pulmonary fibrosis. Gera operates as a lean, science-driven entity leveraging deep expertise in cytokine biology to advance its therapeutic candidates toward clinical trials.